8-K: Allogene Reports Q4/FY25 Results, Cema-Cel & ALLO-329 Updates

Allogene Therapeutics announced its fourth quarter and full year 2025 financial results and provided key updates on its pivotal ALPHA3 and RESOLUTION clinical trials.

Summary

• Allogene Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2025.
• The pivotal, randomized Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation in Large B-Cell Lymphoma (LBCL) is enrolling across more than 60 clinical trial sites.
• An interim futility analysis for the ALPHA3 trial, evaluating MRD clearance and early safety results, is planned for April 2026.
• The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease (AID), which incorporates Dagger technology for built-in lymphodepletion, is enrolling patients in its dose escalation phase.
• Proof-of-concept data from the RESOLUTION trial are planned for June 2026.
• ALLO-316's TRAVERSE trial in renal cell carcinoma (RCC) has completed enrollment in its Phase 1b cohort, and the company is exploring partnering opportunities.
• The company ended Q4 2025 with $258.3 million in cash, cash equivalents, and investments.
• Allogene has extended its cash runway into the first quarter of 2028, attributed to disciplined expense management, focused investment, the return of $23.7 million in escrow funds, and opportunistic use of its at-the-market (ATM) facility.
• Guidance for operating cash expense in 2026 is approximately $150 million, with GAAP Operating Expenses expected to be approximately $210 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update, primarily due to the extended cash runway and the progression of key clinical trials towards significant data readouts, despite ongoing losses typical for a clinical-stage biotech.

Positives

• The pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL is progressing towards an interim futility analysis in April 2026, potentially marking a significant advance in MRD-guided 1L consolidation treatment.
• The ALPHA3 trial's broad site footprint, including community cancer centers, aims to enhance patient access and demonstrate allogeneic CAR T delivery at biologic-like scale.
• The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease is enrolling, with proof-of-concept data expected in June 2026, potentially opening a large new market for cell therapy.
• ALLO-329's Dagger technology is designed to reduce or eliminate the need for conventional cytotoxic lymphodepletion, improving the tolerability profile for CAR T in autoimmune disease.
• The company ended Q4 2025 with a solid cash position of $258.3 million in cash, cash equivalents, and investments.
• The cash runway has been extended into Q1 2028, reflecting disciplined expense management and the return of $23.7 million in escrow funds.
• ALLO-316 remains the only allogeneic CAR T therapy to show clinically significant response rates and meaningful durability of response in a metastatic solid tumor.

Negatives

• Net loss for the fourth quarter of 2025 was $38.8 million, or $0.17 per share.
• Net loss for the full year of 2025 was $190.9 million, or $0.87 per share.
• Research and development expenses for the full year 2025 were $150.2 million.
• General and administrative expenses for the full year 2025 were $56.8 million.
• Cash, cash equivalents, and investments decreased from $373.1 million as of December 31, 2024, to $258.3 million as of December 31, 2025.

Risks

• Risks and uncertainties inherent in clinical development, including that interim or early data may not be predictive of later or final results.
• Patient enrollment and trial execution risks.
• Uncertainties related to MRD testing and its clinical significance.
• The occurrence of adverse safety events.
• Regulatory risks and uncertainties.
• Manufacturing and CMC risks.
• Reliance on third parties and licensors.
• Competitive developments.
• Intellectual property and contractual risks.
• Financial risks, including the need for additional capital.

Future Outlook

The company anticipates significant clinical milestones with an interim futility analysis for the ALPHA3 trial in April 2026 and proof-of-concept data for the RESOLUTION trial in June 2026. It expects to maintain its cash runway into the first quarter of 2028 and has provided operating expense guidance for 2026. Allogene is also actively exploring partnering opportunities to advance its ALLO-316 asset.

Management Comments

• "Allogene is approaching a pivotal inflection point, with the first interim data of cema-cel's ALPHA3 trial just weeks away."
• "We designed ALPHA3 to answer a bold question: can early, MRD-guided allogeneic CAR T prevent relapse in LBCL? We believe that this trial will answer that question and has the potential to mark one of the most significant advances in the field in decades."
• "Importantly, through ALPHA3 we are working to demonstrate that allogeneic CAR T can move beyond academic settings and be delivered at biologic-like scale."
• "Beyond oncology, ALLO-329 demonstrates how our Dagger technology may redefine the delivery of CAR T in autoimmune disease."
• "Supported by a cash runway into 2028, we are focused on disciplined execution and delivering transformative data across our portfolio."

Industry Context

StockSavvy.ai notes that Allogene Therapeutics is strategically positioning itself at the forefront of allogeneic CAR T development, aiming to address critical challenges in both oncology and autoimmune diseases. The ALPHA3 trial's focus on MRD-guided first-line consolidation in LBCL, coupled with its broad site footprint encompassing community cancer centers, signifies a concerted effort to expand the accessibility and scalability of CAR T therapy beyond traditional academic settings. Furthermore, the ALLO-329 program, leveraging proprietary Dagger technology to potentially eliminate conventional lymphodepletion in autoimmune disease, represents a significant innovation that could redefine the delivery and tolerability of CAR T in a large, underserved market, differentiating Allogene from competitors in the rapidly evolving cell therapy landscape.

Comparison to Industry Standards

• ALLO-329's Phase 1 RESOLUTION trial is evaluating dose levels starting at 20 million CAR T cells, which is significantly lower than competitive autologous CAR T programs (approximately 150 million cells) and other allogeneic programs (nearly 1 billion cells), potentially indicating a more potent or efficient therapy due to its Dagger technology.
• ALLO-316 is highlighted as the only allogeneic CAR T therapy to demonstrate clinically significant response rates and meaningful durability of response in a metastatic solid tumor, setting a benchmark for allogeneic CAR T development in challenging solid tumor indications.

Stakeholder Impact

• Shareholders: Potential for significant value creation if ALPHA3 and RESOLUTION trials yield positive results; continued dilution risk from ATM facility use; extended cash runway reduces immediate financing concerns.
• Patients: Potential for new, more accessible, and effective allogeneic CAR T therapies for Large B-Cell Lymphoma and autoimmune diseases.
• Employees: Continued employment and focus on key programs.
• Partners (Servier, Cellectis): Ongoing collaboration and licensing agreements.

Next Steps

• Interim futility analysis for the Phase 2 ALPHA3 trial in April 2026.
• Proof-of-concept data from the Phase 1 RESOLUTION trial in June 2026.
• Exploring partnering opportunities for the ALLO-316 asset.
• Host a live conference call and webcast on March 12, 2026, at 2:00 p.m. PT / 5:00 p.m. ET to discuss financial results and provide a business update.

Key Dates

Recommendation

The company is at a pivotal stage with significant data readouts for its lead programs in April and June 2026. While the extended cash runway is positive, the company remains unprofitable, and the success of its pipeline is speculative. Investors should hold to await these critical data points, which will provide clearer direction on the company's future prospects and potential for transformative advances in CAR T therapy.

Keywords

Allogene Therapeutics, AlloCAR T, cancer, autoimmune disease, LBCL, cema-cel, ALPHA3 trial, ALLO-329, RESOLUTION trial, Dagger technology, lymphodepletion, financial results, biotechnology, clinical trial, oncology, rheumatology